Ashwagandha

Ashwagandha (Withania somnifera) is one of the most-researched adaptogenic herbs in the supplement literature, with clinical research concentrated on anxiety and stress (the dominant use), sleep quality, athletic performance and strength, testosterone and male reproductive health, and cognitive function. The herb has been used in Ayurvedic medicine for centuries; modern supplement research uses standardized root or root-and-leaf extracts, most commonly KSM-66 and Sensoril (two branded extracts that dominate the trial literature). Active constituents include withanolides, steroidal lactones whose mechanisms are still being characterized in modern pharmacology.

The outcome dimensions covered most heavily are anxiety and stress (the supplement's primary established use, anchored by a 2022 WFSBP/CANMAT clinician-guidelines document), sleep quality (a rapidly growing literature with multiple recent meta-analyses), strength and athletic performance, testosterone and male fertility markers (smaller and more contested), and general cognitive function. Cortisol modulation is a consistently-measured biomarker across many of these outcomes; the supplement has well-documented short-term effects on serum cortisol, which is the mechanistic basis often cited across indications.

Demographically, the literature concentrates on healthy adults under stress (the dominant trial population), with substantial subsamples in clinical anxiety, athletic populations, and males with fertility concerns. Specific extract differences (KSM-66 vs. Sensoril vs. generic standardized) is a methodologically important question that the field is still working through; head-to-head comparisons are thinner than the market implies. Trial duration is typically 6-12 weeks, which is shorter than would be ideal for establishing long-term safety and durability of effects.

Ashwagandha is generally well-tolerated in short-to-medium-term trials (typically up to 12 weeks). The most-common adverse effects are mild gastrointestinal discomfort, drowsiness, and headache. Concerns have been raised in the recent literature about possible liver-injury cases, with rare severe cases reported mainly in people with pre-existing liver disease; several national regulators (including in Germany and Australia) have issued cautionary statements about ashwagandha-associated hepatotoxicity, though the absolute risk appears low and the mechanism remains unclear. Drug interactions include theoretical additivity with sedatives and a possible reduced effect of immunosuppressants, plus possible interactions with thyroid hormone, diabetes and blood-pressure medicines, and the herb is generally contraindicated in pregnancy (possible abortifacient effects reported in traditional and preclinical sources). People with autoimmune or thyroid conditions should consult a clinician before use; NIH advises avoiding it during pregnancy and breastfeeding.

This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.